SCHEMBL2262835

SCHEMBL2262835

Cc1ccc(Cn2c(-c3ccc(OC4CCCCC4)cc3)cc(C(F)(F)F)c(C#N)c2=O)c(C)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 4/20 0.51
NR1H3 Q13133 4/20 0.51
RXRA P19793 3/20 0.51
RAPGEF4 Q8WZA2 1/20 0.36
EPHX2 P34913 1/20 0.36
ALDH1A1 P00352 3/20 0.36
GLA P06280 2/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
ATM Q13315 1/20 0.36
NR3C1 P04150 1/20 0.34
AR P10275 1/20 0.34
KDM4E B2RXH2 3/20 0.34
MAPT P10636 1/20 0.34
KCNH2 Q12809 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
GNRHR P30968 1/20 0.33
FFAR1 O14842 1/20 0.33
TNKS O95271 1/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2387518 0.92 RXRA (0.50) NR1H2NR1H3RXRAEPHX2ALDH1A1
SCHEMBL2263468 0.89 NR1H2 (0.49) NR1H2NR1H3RXRARAPGEF4ALDH1A1
SCHEMBL2266401 0.86 GPR119 (0.47) NR1H2NR1H3RXRAEPHX2
SCHEMBL12366885 0.86 NR1H2 (0.36) NR1H2NR1H3RXRAEPHX2KCNH2
SCHEMBL2262644 0.86 RXRA (0.58) NR1H2NR1H3RXRAALDH1A1GLA
SCHEMBL2266726 0.86 NR1H2 (0.65) NR1H2NR1H3RXRAALDH1A1GLA
SCHEMBL2266112 0.85 NR1H2 (0.56) NR1H2NR1H3RXRAALDH1A1GLA
SCHEMBL2262577 0.85 NR1H2 (0.62) NR1H2NR1H3RXRAALDH1A1GLA
SCHEMBL4896265 0.84 NR1H2 (0.61) NR1H2NR1H3RXRAALDH1A1GLA
SCHEMBL12390451 0.84 NR1H2 (0.52) NR1H2NR1H3RXRAALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7998986-B2 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 US disclosed
US-7998986-B2 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 US disclosed
US-20030181420-A1 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors EXELIXIS, INC. 2003-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030181420-A1 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors NR1H2, NR1H3, NCOA1 NR1H2 1/4885NR1H3 2/4885RXRA 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.